I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 72% ± 31% | |
| endothelial cell of sinusoid | 4 studies | 35% ± 9% | |
| hepatic stellate cell | 3 studies | 57% ± 33% | |
| endothelial cell | 3 studies | 65% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 72% ± 31% | |
| endothelial cell of sinusoid | 4 studies | 35% ± 9% | |
| hepatic stellate cell | 3 studies | 57% ± 33% | |
| endothelial cell | 3 studies | 65% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 5 studies | 69% ± 28% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 174714.42 | 226 / 226 | 99% | 28234.70 | 400 / 406 |
| ureter | 0% | 0 | 0 / 0 | 100% | 13.44 | 1 / 1 |
| lung | 90% | 34.42 | 520 / 578 | 4% | 26.64 | 50 / 1155 |
| kidney | 81% | 16.33 | 72 / 89 | 4% | 3.56 | 40 / 901 |
| spleen | 85% | 149.61 | 204 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 84% | 748.08 | 779 / 929 | 0% | 0 | 0 / 0 |
| pancreas | 64% | 12.14 | 209 / 328 | 15% | 231.34 | 27 / 178 |
| stomach | 60% | 9.90 | 215 / 359 | 17% | 29.13 | 50 / 286 |
| adrenal gland | 69% | 13.79 | 179 / 258 | 1% | 0.38 | 2 / 230 |
| uterus | 59% | 14.03 | 101 / 170 | 7% | 9.59 | 31 / 459 |
| brain | 64% | 10.90 | 1680 / 2642 | 1% | 0.57 | 6 / 705 |
| intestine | 51% | 10.23 | 497 / 966 | 12% | 20.83 | 62 / 527 |
| esophagus | 54% | 12.78 | 782 / 1445 | 8% | 17.61 | 14 / 183 |
| adipose | 61% | 29.96 | 740 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 55% | 7.58 | 135 / 245 | 5% | 1.54 | 25 / 502 |
| ovary | 58% | 8.29 | 105 / 180 | 1% | 0.15 | 4 / 430 |
| bladder | 43% | 5.14 | 9 / 21 | 14% | 20.51 | 73 / 504 |
| thymus | 52% | 11.77 | 339 / 653 | 4% | 0.50 | 23 / 605 |
| heart | 54% | 12.98 | 463 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 48% | 11.87 | 645 / 1335 | 0% | 0 | 0 / 0 |
| breast | 47% | 23.06 | 216 / 459 | 1% | 4.45 | 14 / 1118 |
| skin | 39% | 8.69 | 700 / 1809 | 6% | 5.42 | 30 / 472 |
| muscle | 31% | 4.14 | 247 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.68 | 1 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.45 | 1 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0060192 | Biological process | negative regulation of lipase activity |
| GO_0010903 | Biological process | negative regulation of very-low-density lipoprotein particle remodeling |
| GO_0050766 | Biological process | positive regulation of phagocytosis |
| GO_0060621 | Biological process | negative regulation of cholesterol import |
| GO_0018158 | Biological process | protein oxidation |
| GO_0060695 | Biological process | negative regulation of cholesterol transporter activity |
| GO_0030300 | Biological process | regulation of intestinal cholesterol absorption |
| GO_0043627 | Biological process | response to estrogen |
| GO_0009749 | Biological process | response to glucose |
| GO_0006656 | Biological process | phosphatidylcholine biosynthetic process |
| GO_0008203 | Biological process | cholesterol metabolic process |
| GO_0043691 | Biological process | reverse cholesterol transport |
| GO_0031100 | Biological process | animal organ regeneration |
| GO_0046340 | Biological process | diacylglycerol catabolic process |
| GO_0033700 | Biological process | phospholipid efflux |
| GO_0034375 | Biological process | high-density lipoprotein particle remodeling |
| GO_0050996 | Biological process | positive regulation of lipid catabolic process |
| GO_0042157 | Biological process | lipoprotein metabolic process |
| GO_1905920 | Biological process | positive regulation of CoA-transferase activity |
| GO_0032375 | Biological process | negative regulation of cholesterol transport |
| GO_0034384 | Biological process | high-density lipoprotein particle clearance |
| GO_0034374 | Biological process | low-density lipoprotein particle remodeling |
| GO_0034380 | Biological process | high-density lipoprotein particle assembly |
| GO_0051384 | Biological process | response to glucocorticoid |
| GO_0018206 | Biological process | peptidyl-methionine modification |
| GO_0034370 | Biological process | triglyceride-rich lipoprotein particle remodeling |
| GO_0050821 | Biological process | protein stabilization |
| GO_0006641 | Biological process | triglyceride metabolic process |
| GO_0032757 | Biological process | positive regulation of interleukin-8 production |
| GO_0050995 | Biological process | negative regulation of lipid catabolic process |
| GO_0033344 | Biological process | cholesterol efflux |
| GO_0009410 | Biological process | response to xenobiotic stimulus |
| GO_0002719 | Biological process | negative regulation of cytokine production involved in immune response |
| GO_0030301 | Biological process | cholesterol transport |
| GO_0031647 | Biological process | regulation of protein stability |
| GO_0042632 | Biological process | cholesterol homeostasis |
| GO_0009395 | Biological process | phospholipid catabolic process |
| GO_0042627 | Cellular component | chylomicron |
| GO_0005576 | Cellular component | extracellular region |
| GO_0034366 | Cellular component | spherical high-density lipoprotein particle |
| GO_0005769 | Cellular component | early endosome |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0034364 | Cellular component | high-density lipoprotein particle |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0005829 | Cellular component | cytosol |
| GO_0034361 | Cellular component | very-low-density lipoprotein particle |
| GO_0070653 | Molecular function | high-density lipoprotein particle receptor binding |
| GO_0019899 | Molecular function | enzyme binding |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0034190 | Molecular function | apolipoprotein receptor binding |
| GO_0015485 | Molecular function | cholesterol binding |
| GO_0008289 | Molecular function | lipid binding |
| GO_0005543 | Molecular function | phospholipid binding |
| GO_0060228 | Molecular function | phosphatidylcholine-sterol O-acyltransferase activator activity |
| GO_0120020 | Molecular function | cholesterol transfer activity |
| GO_0031072 | Molecular function | heat shock protein binding |
| GO_0055102 | Molecular function | lipase inhibitor activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0031210 | Molecular function | phosphatidylcholine binding |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0005319 | Molecular function | lipid transporter activity |
| GO_0008035 | Molecular function | high-density lipoprotein particle binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | APOA2 |
| Protein name | Apolipoprotein A-II, isoform CRA_a (Apolipoprotein A2) Apolipoprotein A-II (Apo-AII) (ApoA-II) (Apolipoprotein A2) [Cleaved into: Proapolipoprotein A-II (ProapoA-II); Truncated apolipoprotein A-II (Apolipoprotein A-II(1-76))] Apolipoprotein A-II (Apolipoprotein A2) Apolipoprotein (Apolipoprotein A-II) (Plasminogen) |
| Synonyms | Apo(a) hCG_1766509 PLGL |
| Description | FUNCTION: May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism. |
| Accessions | ENST00000468465.5 V9GYS1 V9GYM3 V9GYC1 ENST00000481511.5 V9GYE3 ENST00000491350.1 Q9UBQ9 ENST00000463273.5 ENST00000469730.2 ENST00000470459.6 Q76EI7 ENST00000463812.1 V9GYT0 ENST00000464492.5 ENST00000367990.7 V9GYG9 P02652 |
